0001213900-23-006196.txt : 20230130
0001213900-23-006196.hdr.sgml : 20230130
20230130213534
ACCESSION NUMBER: 0001213900-23-006196
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230126
FILED AS OF DATE: 20230130
DATE AS OF CHANGE: 20230130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kaswan Michael
CENTRAL INDEX KEY: 0001324483
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39421
FILM NUMBER: 23570040
MAIL ADDRESS:
STREET 1: KBL HEALTHCARE ACQUISITION CORP II
STREET 2: 645 MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Orchestra BioMed Holdings, Inc.
CENTRAL INDEX KEY: 0001814114
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 UNION SQUARE DRIVE
CITY: NEW HOPE
STATE: PA
ZIP: 18938
BUSINESS PHONE: 646-343-9298
MAIL ADDRESS:
STREET 1: 150 UNION SQUARE DRIVE
CITY: NEW HOPE
STATE: PA
ZIP: 18938
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp 2
DATE OF NAME CHANGE: 20200603
4
1
ownership.xml
X0306
4
2023-01-26
0
0001814114
Orchestra BioMed Holdings, Inc.
OBIO
0001324483
Kaswan Michael
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE
NEW HOPE
PA
18938
0
1
0
0
Chief Financial Officer
Common Stock, par value $0.0001 per share ("Common Stock")
2023-01-26
4
A
0
133545
A
133545
D
Nonstatutory Stock Option (Right to Buy)
10.00
2023-01-26
4
A
0
192566
A
2032-08-25
Common Stock
192566
192566
D
These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities.
Received in the Business Combination in exchange for 287,194 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock").
The nonstatutory stock options have vested and will vest in equal installments over a three-year period on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022.
Received in the Business Combination in exchange for a nonstatutory stock option to acquire 414,120 shares of Legacy Orchestra Common Stock for $4.65 per share.
/s/ Matthew Schob, Attorney-in-Fact
2023-01-30